Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The efficacy and safety of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetes. A 52-week randomised, treat-to-target, placebo-controlled, double-blinded, parallel-group, multinational, multi-centre trial

Next Previous
Trial Profile

The efficacy and safety of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetes. A 52-week randomised, treat-to-target, placebo-controlled, double-blinded, parallel-group, multinational, multi-centre trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Liraglutide (Primary) ; Insulin
  • Indications Type 1 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms ADJUNCT-ONE
  • Sponsors Novo Nordisk

    • Most Recent Events

    • 01 Dec 2021 Results of post-hoc analysis of two studies (ADJUNCT ONE and ADJUNCT TWO) assessing 26 weeks of liraglutide treatment in type 1 diabetes (T1D), published in the Diabetes, Obesity and Metabolism.
    • 29 Jun 2021 Results of randomized controlled phase 3 trials (ADJUNCT ONE (NCT01836523) and TWO (NCT02098395)), presented at the 81st Annual Scientific Sessions of the American Diabetes Association
    • 20 Dec 2016 Primary endpoint (Change from baseline in body weight) has been met.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top